CD274 and hepatocellular carcinoma: The preliminary data of some combinations demonstrated favorable therapeutic effects such as camrelizumab plus apatinib in advanced triple-negative breast cancer (NCT03394287), advanced cervical cancer (NCT03816553), and advanced HCC (NCT03463876) and sintilimab plus anlotinib in advanced NSCLC (NCT03628521) and PD-L1-positive recurrent or metastatic cervical cancer (284).